Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Transfusion|June 27, 2002
Ex vivo expansion of long-term culture initiating marrow cells by IL-10, SCF, and IL-3Felix Keil, Fariborz Elahi, Hildegard T Greinix, et al.
Clinical Breast Cancer|September 11, 2018
Risk Factors for Local Relapse and Inferior Disease-free Survival After Breast-conserving Management of Breast Cancer: Recursive Partitioning Analysis of 2161 PatientsJosef Hammer, Hans Geinitz, Carsten Nieder, et al.
Critical Reviews in Oncology/Hematology|September 10, 2011
Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questionsPeter Valent, Günther Gastl, Klaus Geissler, et al.
Blood|June 1, 2007
Mosaicism due to myeloid lineage restricted loss of heterozygosity as cause of spontaneous Rh phenotype splittingGünther F Körmöczi, Eva-Maria Dauber, Oskar A Haas, et al.
Radiation Oncology (London, England)|May 16, 2020
Altered fractionation short-course radiotherapy for stage II-III rectal cancer: a retrospective studyHans Geinitz, Carsten Nieder, Lukas Kocik, et al.
Radiation Oncology (London, England)|March 23, 2016
Total body irradiation with volumetric modulated arc therapy: Dosimetric data and first clinical experienceAndreas Springer, Josef Hammer, Erwin Winkler, et al.
Wiener Klinische Wochenschrift|June 14, 2020
A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting : R-EFECT studyAndreas L Petzer, Wolfgang R Sperr, Veronika Buxhofer-Ausch, et al.
Blood|April 18, 2012
Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNetJoëlle Guilhot, Michele Baccarani, Richard E Clark, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2020
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trialPeter C Dubsky, Christian F Singer, Daniel Egle, et al.
Haematologica|April 19, 2012
High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trialAndreas L Petzer, Dominic Fong, Thomas Lion, et al.
Pageof 3